Roche says weight loss drug shows promising results in early trial
Publishing timestamp: 2024-05-16 10:03:34
Summary
Roche's experimental weight loss drug, CT-388, showed promising results in early-stage trial, helping patients with obesity lose significant weight. The drug mimics gut hormones to suppress appetite and normalize blood sugar levels. Roche is competing in the booming market for obesity treatments dominated by Novo Nordisk and Eli Lilly. Analysts also discussed Alphabet and Berkshire Hathaway's Q1 2024 figures.
Sentiment: POSITIVE
Tickers: ROG-CH, LLY, NOVO.B-DK, GOOGL, BRK.A, NVO,
Keywords: biotech and pharmaceuticals, novo nordisk a/s, carmot therapeutics inc, health care industry, eli lilly and co, business, roche holding ag, business news, breaking news, pharmaceuticals, biotechnology,
Source: https://www.cnbc.com/2024/05/16/roche-weight-loss-drug-shows-promising-results-in-early-trial.html